Nov 15, 2010
SANTA MONICA, Calif., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Derycz Scientific, Inc. (OTC Bulletin Board: DYSC), a company pioneering a fresh way of facilitating the flow of information from content publishers to enterprise customers and their constituents, today reported financial and operating results for the three months ended September 30, 2010.
Revenues for the first quarter of fiscal 2011 increased 26% to $6.0 million from $4.8 million for the first quarter of fiscal 2010. Revenue from the Reprints Desk subsidiary increased 31% to $5.3 million from $4.0 million for the prior year period, while revenue from the Pools Press subsidiary decreased slightly to $750,379 from $758,032 for the first quarter of fiscal 2010.
Cost of goods sold increased 28% during the first quarter of fiscal 2011 compared with the prior year period, which is roughly in-line with revenue growth. Gross margin was 14%, compared with 15% for the prior year period.
General and administration expenses for quarter ended September 30, 2010 increased 9% to $1.0 million compared with $945,433 for the quarter ended September 30, 2009. The increase was due to higher expenses from Reprints Desk, including increases in sales and marketing, information technology and accounting personnel. Marketing and advertising expenses for the first quarter of the current fiscal year of $114,526 compare with $38,453 for the prior year period, with the increase due to expanded marketing efforts.
Derycz Scientific reported a net loss of $405,269 or $0.03 per share for the three months ended September 30, 2010, compared with a net loss of $310,691 or $0.02 per share for the three months ended September 30, 2009.
The company had cash and cash equivalent of $2.0 million as of September 30, 2010, compared with $1.9 million as of June 30, 2010.
"We are reporting another quarter of substantial revenue growth, which we attribute to our expanded customer base and publisher agreements, and additions to our technology solutions," said Peter Derycz, president and CEO of Derycz Scientific. "We are pleased that approximately 9% of first quarter revenues came from first-time customers.
"We expect sales increases in fiscal 2011, resulting from current customers spending more on existing products and services, as well as the addition of new customers and new solutions. Among recent achievements, today we announced an expanded board of directors and the appointment of three independent directors giving the company a majority of independent directors and positioning the company's stock to eventually trade on an exchange such as NASDAQ.
"To support continued revenue growth we are aggressively bundling and pricing our products and services, which is impacting gross margin. We see this strategy as an avenue for building our customer base as we concurrently pursue strategies to increase margins," he added.
About Derycz Scientific®
Derycz Scientific, Inc. develops companies, products, services and systems that facilitate the re-use of published content in a manner that helps organizations achieve their marketing, communication and research goals effectively and in compliance with copyright law and regulatory rules. Its wholly owned subsidiary companies include Reprints Desk and Pools Press. Reprints Desk offers a one-stop solution for reprints, ePrints and single articles, and has delivered millions of articles worldwide. Reprints Desk is an innovator in content retrieval and ePrint delivery, and its services are designed to help make effective use of published articles in a copyright-compliant manner. Pools Press has excelled in the reprint market for more than 30 years. It provides professionally printed articles from medical and technical journals; prints booklets, catalogs, pamphlets, direct mail pieces and newsletters; and works with publishers who wish to outsource a portion of or all of their reprints business. For more information, please visit www.deryczscientific.com.
Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in obtaining new customers; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"), including the financial statements and related information contained in the Company's Annual Report on Form 10-K. The Company assumes no obligation to update the cautionary information in this release.
Derycz Scientific, Inc.
Condensed Consolidated Statements of Operations
Three Months Ended
COST OF SALES
General and administrative
Marketing and advertising
Depreciation and amortization
TOTAL OPERATING EXPENSES
LOSS FROM OPERATIONS
NET LOSS BEFORE NONCONTROLLING INTEREST
NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST
NET LOSS ATTRIBUTABLE TO DERYCZ SCIENTIFIC, INC.
NET LOSS PER SHARE:
BASIC AND DILUTED
WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC AND DILUTED
Derycz Scientific, Inc.
Condensed Consolidated Balance Sheets
Cash and cash equivalents
Accounts receivable, net of allowance of $59,061
Other current assets
TOTAL CURRENT ASSETS
PROPERTY AND EQUIPMENT, net of
accumulated depreciation of $355,012 and $317,629
Customer lists, net of accumulated amortization of $50,000
Intellectual property licenses, net of amortization of $336,967 and $297,887
LIABILITIES AND STOCKHOLDERS' EQUITY
Payable on Credit Line
Capital lease obligation, current
Income tax payable
Other current liabilities
TOTAL CURRENT LIABILITIES
CAPITAL LEASE OBLIGATIONS
COMMITMENTS AND CONTINGENCIES
Preferred stock; $0.001 par value; 20,000,000 shares
authorized; no shares issued and outstanding
Common stock; $0.001 par value; 100,000,000 shares
authorized; 13,021,223 shares issued and outstanding
Additional paid-in capital
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
SOURCE Derycz Scientific, Inc.